Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kaja Zuwala is active.

Publication


Featured researches published by Kaja Zuwala.


Advanced Healthcare Materials | 2015

Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.

Benjamin M. Wohl; Anton A. A. Smith; Kaja Zuwala; Jesper Melchjorsen; Martin Tolstrup; Alexander N. Zelikin

Efficacious, potent, and at the same time nontoxic macromolecular prodrugs of ribavirin are designed taking advantage over prodrug activation by the intracellular milieu. Activity of these prodrugs is illustrated in the cells hosting hepatitis C virus replication and also in the cells implicated in the inflammatory response to the viral infection.


Advanced Healthcare Materials | 2015

Polymers Fight HIV: Potent (Pro)Drugs Identified Through Parallel Automated Synthesis

Kaja Zuwala; Anton A. A. Smith; Almar Postma; Carlos Guerrero-Sanchez; Jesper Melchjorsen; Martin Tolstrup; Alexander N. Zelikin

Macromolecular (pro)drugs interfere with the proliferation of HIV through both inhibition of viral cell entry and via intracellular delivery of antiviral drugs. Lead polymer conjugates exhibit longevity of action exceeding that of parent nucleoside analogue drug and are active in primary T cell over at least 72 h.


Mediators of Inflammation | 2013

Characterization of HIV-1 Infection and Innate Sensing in Different Types of Primary Human Monocyte-Derived Macrophages

Elisabeth Diget; Kaja Zuwala; Randi K. Berg; Rune R. Laursen; Stine Søby; Lars Østergaard; Jesper Melchjorsen; Trine H. Mogensen

Macrophages play an important role in human immunodeficiency virus (HIV) pathogenesis and contribute to establishment of a viral reservoir responsible for continuous virus production and virus transmission to T cells. In this study, we investigated the differences between various monocyte-derived macrophages (MDMs) generated through different differentiation protocols and evaluated different cellular, immunological, and virological properties. We found that elevated and persistent HIV-1 pWT/BaL replication could be obtained only in MDMs grown in RPMI containing macrophage colony-stimulating factor (M-CSF). Interestingly, this MDM type was also most responsive to toll-like receptor stimulation. By contrast, all MDM types were activated to a comparable extent by intracellular DNA, and the macrophage serum-free medium-(Mac-SFM-)differentiated MDMs responded strongly to membrane fusion through expression of CXCL10. Finally, we found that HIV infection of RPMI/M-CSF-differentiated MDMs induced low-grade expression of two interferon-stimulated genes in some donors. In conclusion, our study demonstrates that the differentiation protocol used greatly influences the ability of MDMs to activate innate immune reactions and support HIV-1 replication. Paradoxically, the data show that the MDMs with the strongest innate immune response were also the most permissive for HIV-1 replication.


Advanced Healthcare Materials | 2016

Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity.

Tracey M. Hinton; Kaja Zuwala; Celine Deffrasnes; Shawn Todd; Shuning Shi; Glenn A. Marsh; Megan Dearnley; Benjamin M. Wohl; Martin Tolstrup; Alexander N. Zelikin

Macromolecular prodrugs are developed as multiarmed agents against diverse viral pathogens. Lead candidates inhibit infectivity and replication of HIV, Ebola, influenza, measles, RSV, etc-thus being broad-spectrum antiviral agents.


Molecular Pharmaceutics | 2016

Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1

Maarten Danial; Anna H.F. Andersen; Kaja Zuwala; Steffen Cosson; Camilla Frich Riber; Anton A. A. Smith; Martin Tolstrup; Graeme Moad; Alexander N. Zelikin; Almar Postma

In this article a library of polymeric therapeutic agents against the human immunodeficiency virus (HIV) is presented. The library of statistical copolymers of varied molar mass was synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization. The synthesized polymers comprise pendent hydroxyl and sulfonated side chains as well as the reverse transcriptase prodrug lamivudine (3TC) attached via a disulfide self-immolative linker. The glutathione mediated release of 3TC is demonstrated as well as the antiviral efficacy against HIV entry and polymerase activity. Although a high degree of polymer sulfonation is required for effective HIV entry inhibition, polymers with approximately ∼50% sulfonated monomer demonstrated potent kinase independent reverse transcriptase inhibition. In addition, the sulfonated polymers demonstrate activity against DNA-DNA polymerase, which suggests that these polymers may exhibit activity against a broad spectrum of viruses. In summary, the polymers described provide a triple-active arsenal against HIV with extracellular activity via entry inhibition and intracellular activity by kinase-dependent lamivudine-based and kinase-independent sulfonated polymer based inhibition. Since these sulfonated copolymers are easily formulated into gels, we envision them to be particularly suited for topical application to prevent the mucosal transmission of viruses, particularly HIV.


Molecular Pharmaceutics | 2017

Macromolecular Prodrugs of Ribavirin: Structure–Function Correlation as Inhibitors of Influenza Infectivity

Camilla Frich Riber; Tracey M. Hinton; Paulina Gajda; Kaja Zuwala; Martin Tolstrup; Cameron R. Stewart; Alexander N. Zelikin

The requirement for new antiviral therapeutics is an ever present need. Particularly lacking are broad spectrum antivirals that have low toxicity. We develop such agents based on macromolecular prodrugs whereby both the polymer chain and the drug released from the polymer upon cell entry have antiviral effects. Specifically, macromolecular prodrugs were designed herein based on poly(methacrylic acid) and ribavirin. Structure-function parameter space was analyzed via the synthesis of 10 polymer compositions varied by molar mass and drug content. Antiviral activity was tested in cell culture against both low and high pathogenic strains of influenza. Lead compounds were successfully used to counter infectivity of influenza in chicken embryos. The lead composition with the highest activity against influenza was also active against another respiratory pathogen, respiratory syncytial virus, providing opportunity to potentially treat infection by the two pathogens with one antiviral agent. In contrast, structure-function activity against the herpes simplex virus was drastically different, revealing limitations of the broad spectrum antiviral agents based on macromolecular prodrugs.


Journal of Controlled Release | 2018

Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects

Kaja Zuwala; Camilla Frich Riber; Kaja Borup Løvschall; Anna H.F. Andersen; Lise Sørensen; Paulina Gajda; Martin Tolstrup; Alexander N. Zelikin

&NA; Macromolecular (pro)drugs hold much promise as broad‐spectrum antiviral agents as either microbicides or carriers for intracellular delivery of antiviral drugs. Intriguing opportunity exists in combining the two modes of antiviral activity in the same polymer structure such that the same polymer acts as a microbicide and also serves to deliver the conjugated drug (ribavirin) into the cells. We explore this opportunity in detail and focus on the polymer backbone as a decisive constituent of such formulations. Fourteen polyanions (polycarboxylates, polyphosphates and polyphosphonates, and polysulfonates) were analyzed for blood pro/anti coagulation effects, albumin binding and albumin aggregation, inhibitory activity on polymerases, cytotoxicity, and anti‐inflammatory activity in stimulated macrophages. Ribavirin containing monomers were designed to accommodate the synthesis of macromolecular prodrugs with disulfide‐exchange triggered drug release. Kinetics of drug release was fast in all cases however enhanced hydrophobicity of the polymer significantly slowed release of ribavirin. Results of this study present a comprehensive view on polyanions as backbone for macromolecular prodrugs of ribavirin as broad‐spectrum antiviral agents. Graphical abstract Figure. No Caption available.


Chemical Communications | 2014

Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs

Anders Kock; Kaja Zuwala; Anton A. A. Smith; Benjamin M. Wohl; Martin Tolstrup; Alexander N. Zelikin


ACS Macro Letters | 2016

Albumin–Polymer–Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles

Anton A. A. Smith; Kaja Zuwala; Oliver Pilgram; Karen Singers Eiskjær Johansen; Martin Tolstrup; Frederik Dagnæs-Hansen; Alexander N. Zelikin


Chemical Science | 2016

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat

Kaja Zuwala; Anton A. A. Smith; Martin Tolstrup; Alexander N. Zelikin

Collaboration


Dive into the Kaja Zuwala's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Almar Postma

Commonwealth Scientific and Industrial Research Organisation

View shared research outputs
Top Co-Authors

Avatar

Tracey M. Hinton

Australian Animal Health Laboratory

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge